Earnings Expectations - Edwards Lifesciences is expected to report Q4 2024 results soon [1] - The Zacks Consensus Estimate for Q4 2024 revenues is $1.36 billion, indicating an 11.2% decline YoY [3] - The Zacks Consensus Estimate for Q4 2024 net earnings is 55 cents per share, a 14.1% drop YoY [3] - The company projected Q4 2024 total sales between $1.33 billion and $1.39 billion, with adjusted EPS between 53 cents and 57 cents [3] Historical Performance - In the last reported quarter, the company's adjusted EPS of 67 cents matched the Zacks Consensus Estimate [2] - The company's earnings beat estimates in one of the trailing four quarters and matched estimates in the other three [2] - EW has a trailing four-quarter earnings surprise of 0.78% on average [2] Business Segments and Growth Drivers - The company likely gained from its patient-focused innovation strategy, favorable hospitalization trends, and strong global adoption of transcatheter heart valves [5] - The Transcatheter Aortic Valve Replacement (TAVR) arm is expected to have seen continued growth in procedures globally, driven by strong demand for the SAPIEN platform [7] - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment's PASCAL platform likely maintained strong growth momentum globally, supported by differentiated therapies and positive trial results [10] - The Surgical Structural Heart segment is expected to have recorded strong growth, driven by the penetration of premium products like RESILIA technology, MITRIS RESILIA valve, INSPIRIS, and KONECT [12] Challenges and Headwinds - The absence of the Critical Care business operation through September 2024 is expected to have impacted Q4 total revenues [5] - The Critical Care business, sold to Becton, Dickinson and Company for $4.2 billion, recorded $246 million in revenues in Q2 2024, reflecting 7% YoY growth [6] - Regional pressures, particularly in Japan, and slower market growth may have continued to hamper growth in Q4 [8] - Hurricanes in the southeast and a one-time impact from a China distributor rebate adjustment are expected to have impacted TAVR performance [9] - Staffing shortages and geopolitical challenges likely impeded growth in the quarter [13] Quantitative Model Predictions - The company has an Earnings ESP of -0.03% and a Zacks Rank 3, indicating a lower chance of beating estimates [14] Other Medical Stocks to Watch - Masimo (MASI) has an Earnings ESP of +4.05% and a Zacks Rank 1, with an average earnings surprise of 17.10% in the trailing four quarters [15][16] - Merit Medical Systems (MMSI) has an Earnings ESP of +3.03% and a Zacks Rank 2, with an average earnings surprise of 6.42% in the trailing four quarters [16][17] - Cencora (COR) has an Earnings ESP of +0.71% and a Zacks Rank 2, with an average earnings surprise of 2.45% in the trailing four quarters [17][18]

Edwards Lifesciences (EW) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, t ...

Edwards Lifesciences (EW) is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from the strong adoption of premium surgical technologies worldwide. In TMTT (Transcatheter Mitral Triscuspid Therapy) segment, the increasing global uptake of PASCAL and EVOQUE is highly encouraging. Meanwhile, a volatile macro economy and adverse currency impacts may dent Edwards’ growth.In the past year, this Za ...

Investors in Edwards Lifesciences Corporation (EW) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $45.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. ...

Edwards Lifesciences (EW) , following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the differentiated PASCAL technology is highly promising. The company is also advancing toward long-term growth through several initiatives across its businesses. Meanwhile, adverse macroeconomic impacts and currency fluctuations remain a concern for Edwards.In the past year, this Zacks Rank #3 (Hold) stock has dropped 1. ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 12, 2024 /PRNewswire ...

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”), have until this upcoming Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences ...

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=115935&from=4 CLASS PERIOD: Febr ...

RADNOR, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...